Digital Look

Welcome to Digital Look++,
you are not logged in

Nektar Therapeutics (NKTR)

$ 44.05

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-18	1,193.32	682.72	6,030.00¢	8.2	n/a	n/a	n/a	0.0%
31-Dec-19	114.62	(440.05)	(3,780.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-20	152.91	(443.95)	(3,735.00)¢	n/a	n/a	n/a	n/a	0.0%

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-25	43.80	(152.50)	(887.20)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-26	42.13	(190.39)	(842.77)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-27	35.99	(274.26)	(1,016.48)¢	n/a	n/a	n/a	n/a	0.0%

Puretech shares fall as Nektar Therapeutics merg...	11-Oct-2022	ShareCast
Puretech Health confirms possible tie-up with Ne...	07-Oct-2022	ShareCast
Puretech Health confirms possible tie-up with Ne...	07-Oct-2022	ShareCast

Nektar has wider first-quarter loss on Exubera c...	08-May-2008	BayArea.com
Lilly Ends Effort to Develop an Inhaled Insulin ...	08-Mar-2008	New York Times
Nektar cuts 150 jobs; operations chief steps down	13-Feb-2008	BayArea.com

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Forecast figures based on normalised accounts.